>
First big depression advance since Prozac nears FDA approval
February 14, 2019

From Bloomberg:

The U.S. Food and Drug Administration is on the brink of approving a breakthrough drug that could upend the way severe depression is treated.

Johnson & Johnson's esketamine, a close chemical cousin of the anesthetic ketamine, cleared a major hurdle on Tuesday when a panel of outside experts recommended that the FDA approve the treatment. The fast-acting antidepressant, administered via a nasal spray, is being tested in major depressive disorder and suicidal thinking. If approved, it would be the first major therapeutic advance for depression since the introduction of Prozac in 1987.

Prozac and other currently available antidepressants take weeks to work and don't help all patients, so esketamine could mark a significant shift in depression therapy.

Continue reading at Bloomberg...

You may also like

U.S. fertility rate drops to new all-time low

"The report found that the general fertility rate dropped 2% between 2017 and 2018 among girls and women age 15 to 44 nationwide."

CDC says death rate for young adults is rising

"Death rates are on the rise for young and middle-aged U.S. adults, with white and black people experiencing higher mortality than Hispanic people."

Millions should stop taking aspirin for heart health

"Millions of people who take aspirin to prevent a heart attack may need to rethink the pill-popping."